Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)

被引：3
|
作者：
Sauter, Craig S. [1 ]
Riviere, Isabelle [1 ]
Bernal, Yvette J. [1 ]
Wang, Xiuyan [1 ]
Purdon, Terence J. [1 ]
Yoo, Sarah [1 ]
Moskowitz, Craig H. [1 ]
Giralt, Sergio [1 ]
Matasar, Matthew J. [1 ]
Curran, Kevin J. [1 ]
Park, Jae H. [1 ]
Sadelain, Michel [1 ]
Brentjens, Renier J. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL).
    Sauter, Craig Steven
    Riviere, Isabelle
    Bernal, Yvette
    Wang, Xiuyan
    Purdon, Terence
    Yoo, Sarah
    Moskowitz, Craig H.
    Giralt, Sergio
    Matasar, Matthew J.
    Curran, Kevin Joseph
    Park, Jae Hong
    Sadelain, Michel
    Brentjens, Renier J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
    Larson, Sarah M.
    Chen, Yvonne Y.
    Johnston, Jim
    Roy, Sylvain
    Patel, Pinakin
    Benjamin, Jonathan E.
    BLOOD, 2023, 142
  • [3] Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma
    Eugenio Galli
    Federica Sorà
    Stefan Hohaus
    Silvia Bellesi
    Francesco Autore
    Elisabetta Metafuni
    Idanna Innocenti
    John Marra
    Alberto Fresa
    Maria Assunta Limongiello
    Sabrina Giammarco
    Lucia Leccisotti
    Andrea Guarneri
    Patrizia Chiusolo
    Luca Laurenti
    Luciana Teofili
    Nicola Piccirillo
    Andrea Bacigalupo
    Simona Sica
    Bone Marrow Transplantation, 2022, 57 : 837 - 839
  • [4] Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma
    Galli, Eugenio
    Sora, Federica
    Hohaus, Stefan
    Bellesi, Silvia
    Autore, Francesco
    Metafuni, Elisabetta
    Innocenti, Idanna
    Marra, John
    Fresa, Alberto
    Limongiello, Maria Assunta
    Giammarco, Sabrina
    Leccisotti, Lucia
    Guarneri, Andrea
    Chiusolo, Patrizia
    Laurenti, Luca
    Teofili, Luciana
    Piccirillo, Nicola
    Bacigalupo, Andrea
    Sica, Simona
    BONE MARROW TRANSPLANTATION, 2022, 57 (05) : 837 - 839
  • [5] Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.
    Liang, Aibin
    Ye, Shiguang
    Li, Ping
    Huang, Jiaqi
    Zhu, Shigui
    Yao, Xin
    Zhou, Lili
    Xu, Yangyang
    Zhu, Judy
    Zheng, Chengxiao
    Chen, Shiyi
    Lan, Liping
    Lv, Xiaoteng
    Wei, Yutian
    Humphries, Michael
    Yao, Yihong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] CD19/CD22 Dual Targeted (Chimeric Antigen Receptor) CAR-T Therapy for Relapsed or RE Fractory (R/R) B-CELL Non-Hodgkin Lymphoma (B-NHL)
    Zhao, Houli
    Hu, Yongxian
    Nagler, Arnon
    Chang, Alex Hongsheng
    Huang, He
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 44 - 45
  • [7] Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
    Wang, Lixin
    Fang, Chuling
    Kang, Qingzheng
    Huang, Wenfa
    Chen, Ziren
    Zhao, Weiqiang
    Wang, Lei
    Wang, Yiran
    Tan, Kun
    Guo, Xiao
    Xu, Yuanyuan
    Wang, Shuhong
    Wang, Lijun
    Qiao, Jingqiao
    Tang, Zhixiong
    Yu, Chuan
    Xu, Yang
    Li, Yisheng
    Yu, Li
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [8] Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
    Zhou, Xuan
    Tu, Sanfang
    Wang, Chunsheng
    Huang, Rui
    Deng, Lan
    Song, Chaoyang
    Yue, Chunyan
    He, Yanjie
    Yang, Jilong
    Liang, Zhao
    Wu, Anqin
    Li, Meifang
    Zhou, Weijun
    Du, Jingwen
    Guo, Zhenling
    Li, Yongqian
    Jiao, Cheng
    Liu, Yuchen
    Chang, Lung-Ji
    Li, Yuhua
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [9] Phase I Clinical Trial of Autologous CD19-Targeted 19-28z CAR T Cells in Adult Patients With Relapsed or Refractory B-ALL
    Park, Jae H.
    Riviere, Isabelle
    Wang, Xiuyan
    Bernal, Yvette
    Halton, Elizabeth
    Quintanilla, Hilda
    Curran, Kevin
    Sauter, Craig
    Sadelain, Michel
    Brentjens, Renier J.
    MOLECULAR THERAPY, 2015, 23 : S188 - S189
  • [10] CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Sauter, Craig S.
    Senechal, Brigitte
    Riviere, Isabelle
    Ni, Ai
    Bernal, Yvette
    Wang, Xiuyan
    Purdon, Terence
    Hall, Malloury
    Singh, Ashvin N.
    Szenes, Victoria Z.
    Yoo, Sarah
    Dogan, Ahmet
    Wang, Yongzeng
    Moskowitz, Craig H.
    Giralt, Sergio
    Matasar, Matthew J.
    Perales, Miguel-Angel
    Curran, Kevin J.
    Park, Jae
    Sadelain, Michel
    Brentjens, Renier J.
    BLOOD, 2019, 134 (07) : 626 - 635
12345